Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) has made billions on coronavirus vaccines. Governments rushed to vaccinate their citizens. 67% of Americans are completely immunized.
These vaccine leaders’ revenue isn’t over yet. That’s because the globe needs booster shots. Moderna and Pfizer have sought the FDA to approve their omicron-specific boosters for fall. Which stock is ideal for this new phase? So, let’s find out.
Moderna’s Case
Moderna (NASDAQ:MRNA) was the first to discuss its omicron-specific booster. The company shared positive clinical study data first. Moderna (NASDAQ:MRNA) stated its booster candidate is effective against BA.4 and BA.5.
The U.K. approved the company’s coronavirus and omicron booster. Last week, Moderna submitted to FDA. It’s for 18-and-up. Moderna has worked closely with the FDA, developing a booster following FDA guidelines. FDA backs omicron-specific boosters. In June, the agency recommended boosters cover this variation.
The U.S. ordered 66 million doses of Moderna for $1.74 billion, with an option for 234 million more. Booster sales could be substantial if demand is high.
Moderna (NASDAQ:MRNA) has said it can update boosters for certain countries. Coronavirus will persist, say experts. And varieties have grown. This could be the first of many Moderna version boosters.
Pfizer’s Case
Pfizer (NYSE:PFE) submitted to the FDA before Moderna. The company leads in other sectors. The U.S. ordered $3.2 billion worth of vaccines from Pfizer. This includes the original vaccine and booster. The country can buy 195 million more doses.
Moderna and Pfizer (NYSE:PFE) may sell the U.S. 300 million doses. Pfizer has gained market share.
The immunized populace is another Pfizer (NYSE:PFE) benefit. It’s for 12 and older. Pfizer may lead to vaccinating teens. Pfizer’s first teen vaccination was approved a year before Moderna. First-to-market advantage. Older people are more prone to coronavirus, and rival Moderna stated that at-risk populations are the target market. Younger users might add revenue over time.
Pfizer (NYSE:PFE) has also committed to swiftly updating vaccinations and boosters. Both firms’ mRNA technology allows this. Traditional vaccines require long processes, while mRNA vaccines don’t.
Which Is Better, Moderna or Pfizer?
Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) should succeed in this new vaccine phase. Who’ll win? Pfizer will likely lead in vaccine sales. The business plans to increase U.S. doses. It can target a more comprehensive age range.
Moderna (NASDAQ:MRNA) may have more stock market potential. Despite billions in revenue and profit, the shares are down more than Pfizer’s.
A good booster season could show Moderna’s success can persist beyond the first COVID-19 immunizations. Moderna is cheaper. The stock is worth 5.1 times projected earnings. Compared to Pfizer’s 7+.
Moderna (NASDAQ:MRNA) is riskier than Pfizer (NYSE:PFE). The coronavirus vaccine is its only marketable product; however, it has numerous promising late-stage prospects. Pfizer sells pharmaceutical blockbusters. Moderna may be the greatest bet for bold investors. Conservative investors may favor Pfizer.
Featured Image: Megapixl @Sigoisette
Author Shariq Khan 
